NCT07871591Not yet recruiting
TOP-CABG Trial: Follow-up Extension (TOP-CABG FE)
Extended Follow-up Study of the Efficacy and Safety of De-escalated Antiplatelet Therapy After Coronary Artery Bypass Grafting (TOP-CABG FE)
Source: ClinicalTrials.gov · Last updated 13 Oct 2026
Brief summary (registry, in English)
To further evaluate the long-term effects of the two antiplatelet strategies on saphenous vein graft patency, long-term adverse cardiovascular events, and bleeding events after coronary artery bypass grafting (CABG), we plan to conduct an extended follow-up study based on the previously completed TOP-CABG trial. This extended follow-up aims to provide high-quality evidence to inform more optimized and individualized long-term antiplatelet management strategies for patients after CABG.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 2290 (estimated)
- First submitted
- 6 Oct 2026
- Start date
- Oct 2026
- Primary completion date
- Dec 2027
- Lead sponsor
- China National Center for Cardiovascular Diseases
- Diseases
- Coronary artery disease
- NCT number
- NCT07871591
What you commit to
- Study type: Observational
- Planned participants: 2290
- From Oct 2026 to the primary completion date, Dec 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Concomitant valve (excluding aortic bioprosthesis), aorta, or rhythm surgery during the same session.
- Use of other antiplatelet drugs than aspirin or ticagrelor (clopidogrel, prasugrel, etc) and unable to discontinue this medication after CABG, in the treating physician's or the investigator's opinion.
- Patients who take oral anticoagulants before CABG and have to use anticoagulants after surgery.
- Contraindication for the use of ticagrelor or aspirin (ie. history of bleeding diathesis within 3 months prior presentation, severe gastrointestinal bleeding within 1year prior presentation, peptic ulcer without gastrointestinal bleeding in past 3 years or history of intracranial hemorrhage, allergy, severe gastrointestinal reaction caused by aspirin).
- Placement of a drug-eluting stent in a coronary or cerebral artery within 6 months of CABG or placement of a bare-metal stent in a coronary or cerebral artery within 1 month of CABG
- Use of strong inhibitors of CYP3A4
Other illness
- Patients with single coronary artery disease.
- Patients with sick sinus syndrome, 2nd or 3rd atrioventricular block.
- Patients with contraindications for coronary computed tomography angiography or coronary angiography (eg. contrast allergy).
- Patients with active malignant tumors with increase in bleeding risk in the investigator's opinion
Lab values
- Thrombocytopenia before CABG (\< 100 x 109/L).
- Patients with severe renal function impairment requiring dialysis or active liver disease, including patients with unexplained persistent elevated transaminase or any transaminase more than 3 times the normal limit.
Other
- Patients undergo emergency CABG.
- Patients with cardiogenic shock and hemodynamic instability.
- Patients who have to use methotrexate and ibuprofen.
- Pregnant patients, patients who have given birth within the past 90 days, or who are breastfeeding.
- Premenopausal women who do not take adequate contraception. Adequate contraception refers to the adoption of at least two reliable methods of contraception, one of which must be a barrier method of contraception.
- CABG volume of the surgeon less than 50.
Who the study is looking for
- Patients 18-80 of age.
- Patients undergo planned CABG for the first time with ≥1 SVGs
- Patients with written informed consent.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.